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Purpose: Opioid maintenance treatment reduces a person’s use of heroin. However, fre-
quent substance use in treatment is a problem.
Aim: To examine the association between opioid maintenance treatment and opioid/poly-
drug use, and whether social factors, adverse experiences, social resources, and quality of life
are associated with opioid/polydrug use during the first 12 months in treatment.
Patients and Methods: Forty-seven participants from treatment units in Bergen, Norway
participated in five waves of data collection. Every third month, a structured face-to-face
interview collected self-reported data on sociodemographic characteristics, opioid/polydrug
use, participants’ social resources or adverse experiences, and quality of life. Data were
collected as part of KVARUS, the National Quality Register for Substance Abuse Treatment.
A multilevel binary logistic regression analysis was conducted to examine the association of
opioid/polydrug use and time in current treatment. The analysis included regressions of
opioid/polydrug use on time-invariant baseline adverse experiences and social resources, and
time-varying reports of quality of life.
Results: Therewas a significant negative association between time in treatment and use of opioids,
b =−0.89, SE = 0.19, p = <0.01. Furthermore, a negative association of age at substance use on
polydrug use was found, b =−0.40, SE =0.19, p = 0.03. A higher overall quality of life was
significantly associated with lower odds of opioid use during opioid maintenance treatment, b =
−0.62, SE = 0.23, p = < 0.01. Social dimensions, participants’ adverse experiences, and social
resources were not associated with polydrug or opioid use.
Conclusion: Opioid maintenance treatment is associated with lowered opioid use, but to
a lesser degree with polydrug use. Our findings add quality of life as an important factor that
should be given particular attention because it can offer insight to aspects that can affect the
patients’ opioid use.
Keywords: opioid maintenance treatment, polydrug use, opioid use, patient reported
outcome measures, quality of life
Introduction
Opioid Maintenance Treatment (OMT) reduces use of heroin,1–3 retains patients in
treatment,3,4 and decreases criminal activity4,5 and mortality.2,6 Today, OMT is the
most common and effective treatment for opioid dependence.3,7–10 To illustrate the
effectiveness of OMT, Tran, Ohinmaa, Mills, et al11 found that the proportion of
self-reported opioid use among patients in OMT with continued opioid use
decreased from 99.7% from baseline to 14.6% at 9-month follow-up.
The positive effect of OMTon heroin reduction might not generalize to reduced use
and misuse of other legal and illegal substances. Several sources reported misuse of
alcohol, benzodiazepines (BZD), amphetamines, cannabis, cocaine, and OMT
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medications.7,10,12–14 Synthetical opioids such as methadone,
buprenorphine, and fentanyl are increasingly misused.10
Frequent substance use and polydrug use in OMT is a -
problem,8,9,15 and such use is associated with dropout from
OMT.16,17 Drug use in early OMT is indicative of proble-
matic or negative response to treatment. White, Campbell,
Spencer, Hoffman, Crissman, DuPont18 found that OMT
patients with positive test for polydrug use had quadrupled
the attrition rate, with the highest attrition rate among patients
who used opiates or non-prescribed BZD, 46% and 42%,
respectively. In contrast, those without positive drug tests had
a 10% attrition rate.
The magnitude of polydrug use among OMT patients
has received little research attention.7 A study showed that
among OMT patients in Canada, 93.3% had used illicit
substance, and 85% tested positive for polydrug use indi-
cated by ≥ 2 illicit drug classes in the same test.17 Soyka,
et al2 found that OMT patients in Germany increased use of
alcohol, cannabis, and cocaine from baseline to 12 months,
and at six-year follow-up. The study also showed that
patients underreported the use of BZD, and urine tests
identified 20% used BZD while in OMT.2 Specka, et al12
found that 25% of all OMT patients had a constantly high
BZD-positivity rate, and usually in combination with addi-
tional substances. A recent study among 434 patients in
opioid agonist treatment in Ukraine showed that 23%
injected drugs the previous 30 days, primarily opioids, and
of these 40% had polydrug use with opioids, stimulants, and
alcohol.19 A Chinese study showed that 74.6% of OMT
patients used opioids more than once during the 12 months
after treatment initiation.20 Wagner, et al7 found that 51% of
patients with minimum 1 week in OMT had positive tests
for at least one non-prescribed substance, and 32% tested
positive for substances that were not part of the routine drug
screening, such as Pregabalin.
There are multiple determinants for substance use, e.g.
polydrug and/or opioid use, among OMT patients. Substance
use refers to the use of one substance, either illegal or legal,
while polydrug use refers to the use of multiple substances
consumed sequentially or at the same time.21 Having a history
of polydrug use, history of injecting22 and a desire to get
intoxicated predict continued polydrug use during OMT.
However, Moratti, Kashanpour, Lombardelli, Maisto23 sug-
gest that experience of euphoria or pleasure is seldom themain
reason for substance and polydrug use. Other potential factors
are self-treatment of opioid dependence where the person tries
to reduce withdrawal symptoms and cravings,24 the type of
OMT medication,22 and inadequate dosage.15,22,23,25,26 Side
effects of OMT medications can lead patients to prefer alter-
native to OMT medication.27 Tran, et al11 found that ongoing
substance abuse was significantly predicted by peer pressure,
cravings, having health concerns and receiving treatment for
tuberculosis.
In addition to these individual factors, social conditions
might be contributing factors in polydrug use during OMT as
well. Poorer social conditions, such as no work and income,
and ongoing substance use have been associated with injected
buprenorphine among OMT patients.28 According to Kopak,
Proctor, Hoffmann29, patients age (younger than 25 years),
low income (earning less than a high-school diploma), marital
status (never been married), and employment status (unem-
ployed) were important indicators in relation to post-
treatment substance use. Lack of psychosocial support during
treatment is also associated with injecting use of intoxicating
substances.22 Maintaining contact with active drug users and
participating in a drug-use lifestyle are negative effects of
polydrug use which can reduce the probability of successful
outcome from OMT.30 Besides, a childhood with only one or
no parents, not living in a stable relationship and being
dissatisfied with treatment are significantly associated with
sniffing of buprenorphine among OMT patients.31
Social and environmental influences can be a part of
multiple causes for ongoing substance abuse among
patients in OMT. As concurrent substance use might lower
retention rate in OMT,16,18 it is important to understand and
examine the determinants of concurrent use. Knowledge
about these factors is a perquisite for improving interven-
tions, retention and outcomes of OMT. On this background,
our study addresses the following research objectives:
(a) to examine the association between OMT and sub-
sequent substance/polydrug use and,
(b) to examine whether social factors such as social
background, adverse experiences, social resources,
and quality of life (QOL) are associated with sub-
stance and polydrug use during the first 12 months
after enrolment in OMT.
Materials and Methods
Sample
Eligible participants were first-time OMT patients in the
catchment area of Haukeland University Hospital, Bergen,
Norway. In 2018 there were 1080 OMT-patients in this
catchment area. Approximately 100 new patients were
enrolled on a yearly basis. OMT patients were recruited
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from eight outpatient OMT units, during two periods:
January to December 2013, and September 2015 to
June 2016. The majority of participants were outpatients,
but some participants were imprisoned. At the outpatient
unit, patients picked up their daily medicine and had a short
conversation with one of the OMT staff, while participants
in prison got their medication from health professionals or
prison staff. Participants received either buprenorphine (4 to
20 mg/day) or methadone (80 to 100 mg/day). Two partici-
pants got a muscle injection of extended-release naltrexone
once a month.
Inclusion criteria were first time admittances to OMT,
opioid dependence according to ICD-10 or DSM-IV, age >
18 years, commencement of OMT medication (buprenor-
phine or methadone) before the first registration. Lack of
competence to consent was the only exclusion criterion.
One hundred and 39 OMT patients were contacted and
invited to participate in our study. All of these 139 fulfilled
the inclusion criteria. Of these, 15 declined to participate,
while 77 OMT patients did not respond to the invitation.
Forty-seven self-recruited opioid-dependent individuals in
OMTwere enrolled in the study. Data from these 47 partici-
pants were included in the analysis up to the time participants
completed the research participation. Participants received
a lottery ticket for every fulfilled data point. At the 12-month
data point, participants received a gift card valued for 200
NOK (approximately 22 USD or 22 EUR) in addition to the
lottery ticket.
During the first year of data collection, 10 participants
dropped out. Five participants dropped out without reason,
three withdrew due to lack of interest, one was excluded due
to cognitive impairment and inability to provide consent,
and one participant was impossible to get in touch with. For
complete information see Carlsen, Lunde, Torsheim.32
Data Collection
Structured face-to-face interviews were completed by using
the KVARUS questionnaire (National Quality Register for
Substance Abuse Treatment). The KVARUS applies to
individuals with a substance use disorder enrolled in treat-
ment, and data in KVARUS are patients’ subjective percep-
tions on given topics. The KVARUS is described in detail
elsewhere, see Carlsen, Lunde, Torsheim.32
We utilized data from a three-monthly interval from base-
line (T0) through the first 12-month follow-up (T1–T4, where
T1 is after 3months, T2 is after 6months, T3 is after 9months,
and T4 after 12 months). Between 169 and 193 observations
were collected from a total of 47 participants. These data were
analysed and distributed as follows: 47 participants at T0, 38
participants at T1 and T2, 34 participants at T3 and 36 parti-
cipants at T4.
Participants provided written informed consent. The
principal investigator had the main responsibility for data
management. The study was approved by the Regional
Committee for Medical and Health Research Ethics
(2013/429/REK South-East C).
Measures
In the current study, information on sociodemographic
characteristics, substance use, social resources, adverse
experiences, and QOL was collected.
Measured sociodemographic characteristics were level of
education (no education/primary-secondary school/high
school, higher education), marital status (single/cohabitant/
boy-girlfriend), and living situation (own apartment/perma-
nently with family/temporary living arrangement/homeless).
Substance use over the last 30 days was measured by
the participants’ self-reported 1) opioid use such as heroin,
non-prescribed opioids, like methadone, buprenorphine-
naloxone (Suboxone®), buprenorphine, morphine, other
opioids, or overuse or misuse of prescribed opioids,
and 2) use of substances such as alcohol, cannabis, BZD,
GHB/GBL, hallucinogens, amphetamine, cocaine, and
other stimulants. Participants’ use of OMT medication
(methadone, buprenorphine-naloxone (Suboxone®) or
buprenorphine) as prescribed was not considered as opioid
use. However, participants’ self-reported misuse or over-
use of opioids were categorised as opioid use, and use of
other substances were categorised as polydrug use.
Significant life events can be experienced as social
resources or adverse experiences. Adverse experiences are
traumas or life events that the participants consider as having
a negative impact on their current life. Dropout from school,
addictions in participants’ close family, neglect and being
under care are indicators of adverse experiences found in
KVARUS. Examples of social resources measured in
KVARUS are support from family members, having drug-
free friends, a safe and good housing situation and being in
a stable relationship. These indicators were measured by
“yes” or “no” responds. The yes responds to the various
indicators of social resources were grouped into one variable,
measuring the total social resources the participants
accessed. In addition, the yes responds for the adverse experi-
ence indicators were grouped into one variable measuring the
total adverse experience participants had been exposed to.
Dovepress Carlsen et al
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The current study used general and domain-specific mea-
sures of QOL. Overall QOL was measured by the item: How
would you rate your QOL as a whole?33 The questions to
measure the domain-specific QOL were: How satisfied are
you with: 1) your relationship with friends,33–35 2)
housing,33,36 3) your health,33,34 4) leisure,36 and 5) financial
situation.36 Responses were given on a 5-point Likert-type
response scale, ranging from 1 = “very dissatisfied” to 5 =
“very satisfied” at each measurement point.
Data Analysis
To predict dichotomized outcomes from categorical and con-
tinuous predictors we used multilevel binary logistic regres-
sion analysis, as implemented in the Stata melogit program.
The analysis process was conducted in two stages: in the first
stage, the objective was to examine the association of use of
opioids or other substances and time in treatment. We con-
ducted a two-level binary logistic regression with polydrug
use/opioid use as the dependent variable. The independent
variables were time (cumulative from T0 to T4), overall
QOL, level of education, marital status, and living situation.
The second stage of the main analysis included regres-
sions of polydrug use/opioid use on time-invariant baseline,
adverse experiences and social resource, and time-varying
reports of QOL and social factors such as marital status,
housing, and education. We also tested for associations
between polydrug use/opioid use and participants self-
reported social resources and adverse experiences. Various
social life domains can be reflected in specific QOL indica-
tors that are strongly related to global life satisfaction.35 We
therefore tested for specific QOL domains such as partici-
pants’ relationships with friends, their health, leisure, hous-
ing, and financial situation.
The n varies in the different analyses due to non-
response on some of the time-varying covariates included.
For this reason, the current study used between 193 and
146 observations in the data analysis. To test whether there
was a difference at baseline between participants who
dropped out and participants who completed the study,
we conducted a Fisher’s exact test. A confidence interval
of 95% was set, and a p-value of <0.05 was considered
statistically significant in all the analyses.
Results
Attrition
There was attrition from baseline to 12-month follow-up.
Five participants only completed baseline registration.
Four participants missed three data points, one participant
missed two data points, and eight participants missed one
data point. Twenty-nine participants completed all data
points from T0 to T4.
There was no statistically significant association between
attrition pattern and polydrug use from T0 to T4 (baseline to
12-month follow-up) by Fisher’s exact test, baseline p = 0.60,
3 months p = 1.000, 6 months p = 1.000, 9 months p = 1.000,
and 12 months p = 0.42, respectively. Likewise, no signifi-
cant difference was found from T0 to T3 (baseline to 9
months follow-up) between attrition pattern and illegal
opioid use, p = 0.53, p = 0.42, p = 0.20, p = 1.000, respec-
tively. However, patients that dropped out at T4 had a higher
polydrug use at T0, compared to non-dropouts, p = 0.02.
Sociodemographic Characteristics
Participants were mainly Norwegian men, 76.6%, with
a mean age of 37.8 years (SD = 8.58) at baseline. The
mean age at substance use onset was 14.3 years (SD =
4.87), while age at opioid onset was 22.6 years (SD =
6.80). At baseline, 78.7% of participants were not in
a relationship. About half of the participants, 51.1%, lived
in their own apartment, while 29.8% had a temporary-living
situation, e.g. prisons, rehabilitation homes or treatment
institutions, and 14.9% lived with their family. With regard
to the education level, 45% of the participants’ had primary/
secondary school while 27.7% had high school as their
highest education. Approximately half of the participants
had children, 53.2%; however, only 8.5% had custody for
children under 18 years of age. About one-third, 29.7%, had
visitation rights. Other sociodemographic characteristics
were reported in Carlsen, Torsheim.37 For sociodemographic
distribution on study variables, see Table 1.
Illegal Substance and Opioid Use
At baseline, 70.2% of participants who reported substance
use within the last 30 days stated opioids as the used
substance. In this context, the use of opioids mainly con-
sisted of heroin or illegal use of buprenorphine. The fre-
quency of usage varied from single days to daily use of
opioids during the last 30 days. In addition to opioid use,
participants reported polydrug use that usually consisted of
cannabis, BZD, amphetamine, and alcohol. Use of these
illegal substances was also reported at the follow-up per-
iods. Benzodiazepines and cannabis were often used in
combination with other substances. Figure 1 shows the
results from opioid and polydrug use on time.
Carlsen et al Dovepress
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There was no association of time, b =−0.01, SE = 0.16,
CI [−0.33, 0.30], p = 0.93, on polydrug use. However,
a significant relationship between time and use of opioids
was identified, b = −0.89, SE = 0.19, CI [−1.28, −0.50],
p = <0.01. Participants had a significant reduction in
opioid use during the first 12 months; especially within
the first 3 months see Figure 1.
The result showed a significant relationship between
age at substance use onset and polydrug use, b = −0.40,
SE = 0.19, CI [−0.77, −0.02], p = 0.03, indicating that the
older the age at onset the lower the polydrug use in OMT.
However, no such association was found between age at
opioid onset and opioid use.
Social Background
Multilevel binary logistic regression showed that marital
status was not associated with polydrug use or opioid use.
Education level was overall not related to polydrug or
opioid use. Compared to other housing situations, we
found that living in a treatment institution or in prison
were significantly related to having less polydrug use,
b = −2.53, SE = 0.81, CI [−4.13, −0.93], p = 0.002.
In the last sequence, a multilevel logistic regression tested
the associations between the dependent variable and partici-
pants’ social resources, their adverse experiences, age at sub-
stance onset, age at opioid onset, follow-up time, and QOL.
For opioid use, pre-baseline history of adverse experi-
ences and social resources were not significantly asso-
ciated with opioid use during OMT. Overall QOL during
OMT was significantly associated with opioid use, indicat-
ing that higher QOL was related to lower odds of opioid
use during OMT b =−0.62, SE = 0.23, 95% CI [−0.16,
−0.22], p = <0.007.
Adverse experiences and social resources were not
significantly related to polydrug use during treatment.
However, age at substance use onset was significantly
associated with polydrug use, see Table 2. No interrela-
tions between the other independent indicators and poly-
drug use were identified.
Interaction effect analysis revealed no significant Time
by Total adverse experiences interaction, Time by Total
resources interaction, or Time by Age at substance use
onset interaction (not shown in tables), indicating that
these background factors did not moderate the slope of
change in OMT.
In follow-up analysis we tested polydrug use/opioid
use and domain-specific QOL indicators, such as housing,
leisure, family and friends, health, and financial situation,
but none of these specific domains of QOL were asso-
ciated with opioid use or polydrug use.













Age at substance use onset 14.3 4.87




Social resources 8.61 4.82
Adverse experiences 9.82 4.47
Quality of Life
Overall Quality of Life 2.27 1.41





Financial situation 2.14 1.10
Note: Sample size domain-specific QOL vary between 44 and 47 participants,























































Figure 1 Polydrug use and opioid use regressed on time (follow-up time T1–T4).
Note: Sample size baseline 47.
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Discussion
Our main finding is that OMT is significantly related to
opioid use among opioid-dependent individuals’, espe-
cially during the first year. This is also in line with pre-
vious studies.1,2,38 OMT aids the withdrawal symptoms
and the continuous hunt for the next fix for the patients.
The fact that some OMT patients have a concurrent opioid
and/or polydrug use is a discussion of whether OMT
patients’ make use of the treatment or not, and this is of
clinical, social, and political interest. Lack of psychosocial
support has been associated with the use of legal and
illegal substance use in OMT.22 Some participants in our
study highlighted the treatment system in itself as a reason
for polydrug use. They experienced “being a part of
a machinery”, where the treatment consisted of daily dis-
tribution of medicine and a brief conversation with the
staff at the outpatient unit. Participants expressed a need
for psychological treatment, more medical follow-up with
a more flexible tapering of illegal use, such as BZD, and
help with social challenges, e.g. related to daily activities
as well as assistance with their housing situation. On the
basis of lack of psychosocial treatment and inadequate
help in OMT, many OMT patients used their well-known
coping strategies, namely polydrug use. One solution to
reduce patients’ opioid use and/or polydrug use can per-
haps be found in the actual treatment system, i.e. what
type of treatment, the treatment content and treatment
alternative patients are offered as well as addressing
other burdens they bring along into treatment. Norway
has a Cooperation reform (Samhandlingsreform) that was
implemented to develop a better public health, prevention
and a better health and care services.39 This Cooperation
reform provides guidelines for interaction across munici-
pal and national institutions, but these strategies might not
be very effective when it comes to OMT patients. In
addition, Lions, Carrieri, Michel, et al40 found that
a good relation to their physician could help OMT patients
to abstain from none-prescribed opioid during treatment.
Abstinence has been the main objective for treatment of
opioid addiction as well as a measure and outcome of treat-
ment success.41,42 Nevertheless, addictions are often inter-
twined with social, economic, health and mental issues, and
a more holistic and patient-oriented perspective has recently
been emphasized. According to Van den Brink, Haasen43
only motivated patients with sufficient social support and
stable living situations would benefit from abstinence-
oriented interventions. Considering this, the treatment sys-
tem and clinicians might have to accept that not all patients
want to, or are motivated to stop using substances and that
abstinence, for many, is a utopia. From a harm reduction
perspective, perhaps the treatments system should, to
a greater extent than today, help OMT patients to gain
a controlled polydrug use, and if tapering of OMT medica-
tion and abstinence was desired it should be seen as
a treatment bonus. The definition of a successful treatment
may vary from the patients’ perspective to the clinicians’
perspective. Outcome measures that take the perspective of
the patient’s into account will be beneficial, and QOL is such
a measure. To improve the QOL for opioid-dependent indi-
viduals is one of the goals for OMT in Norway.44 Our
research found that overall QOL has a specific relation to
opioid use, and overall QOL seems to be an important
Table 2 Indicators for Opioid Use and Polydrug Use for Participants in OMT
Opioid Usea Polydrug Useb
B SE p z 95% CI B SE p z 95% CI
LL UL LL UL
Intercept 4.08 1.82 0.025 2.24 0.50 7.66 5.75 2.09 0.006 2.74 1.64 9.86
Time c −0.89 0.19 0.001 −4.5 −1.28 −0.50 −0.01 0.16 0.938 −0.01 −0.33 0.30
QOL −0.62 0.23 0.007 −2.68 −1.07 −0.16 −0.22 0.21 0.288 −1.06 −0.65 0.19
Substance use onset −0.40 0.19 0.035 −2.11 −0.77 −0.02
Age of opioid onset −0.07 0.04 0.088 −1.71 −0.15 0.01
Adverse experiences total −0.10 0.06 0.139 −1.48 −0.23 0.03 −0.12 0.10 0.256 −1.14 −0.33 0.08
Resources total 0.05 0.06 0.333 0.97 −0.05 0.17 −0.12 0.10 0.229 −1.2 −0.31 0.07
Notes: aOpioid use = use of substances such as heroin, morphine, non-prescribed opioids like methadone, buprenorphine-naloxone (Suboxone®), buprenorphine, other
opioids, or overuse/misuse of prescribed opioids. Sample size 43 participants with 169 observations, number of missing data 4. bPolydrug use = multiple consumption of
substances such as: alcohol, cannabis, BZD, GHB/GBL, hallucinogens, amphetamine, cocaine, and other stimulants. Sample size 46 participants with 180 observations,
number of missing data 1. cTime = change per 3-month period.
Abbreviations: CI, confidence interval; LL, lower limit; UL, upper limit.
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indicator across time in OMT. This adds to the range of
research that emphasizes the importance of QOL as an out-
come measure.45,46
Mutasa47 found several factors for OMT patient’s con-
current substance use: peer association, social exclusion,
unemployment, poor education, poverty, personality trait
(such as low self-esteem and anxiety), and lack of struc-
ture in everyday life. Brewer, Catalano, Haggerty, Gainey,
Fleming48 found that employment problems/unemploy-
ment and relationship with substance using peers did pre-
dict longitudinally continued substance use. We found that
participants’ social characteristics were associated with
neither opioid nor polydrug use during the first 12 months
of OMT. Our results are in line with Brewer, et al48 who
showed that most of the demographic variables had weak
or non-existing associations with continued substance use.
There is evidence for an association between traumatic
experiences from childhood and substance abuse,49–51
and age at first injection drug use.52 In a previous
publication,37 we found that OMT participants differed in
their exposure to adverse events, and this exposure was
systematically related to age at opioid use onset. However,
we did not find any associations between participants’
adverse experiences or social resources, and their polydrug
or opioid use during the 12-month follow-up.
Previous research identified an association between
young age and polydrug use.53,54 This association is
complex and potential factors can be: being young and
“undergoing renovation” you might be more vulnerable
compared to when one is older. Besides, a feature of
being young is to be a bit more exploratory and maybe
being more exposed to adverse experiences that one
might not have the right prerequisites or life experiences
to deal with in a good way. Another important factor is
the peer-pressure that might be harder to resist when one
is young and not that self-confident. Brewer, et al48
emphasized that younger and unmarried subjects were
more likely to continue substance use compared to older
and married subjects. The same tendency was found in
a Swedish study by Davstad, Stenbacka, Leifman, Beck,
Korkmaz, Romelsjo,55 where age was related to the pro-
portion of discharged OMT patients. Patients at age ≤30
had a higher discharge rate than patient aged ≥41 years,
and 45% of involuntarily discharges were based on sub-
stance use often in relation to other discharge criteria.
A similar association was found in our study: younger
age at substance use onset was significantly related with
a higher polydrug use while in OMT. However, we did
not find an association between age at opioid onset use
and opioid use while in OMT. This is in contrast to
Soyka, Zingg, Koller, Kuefner56 which stated that age
at commencement of continuous opioid use was signifi-
cantly related to treatment dropout: the younger the par-
ticipant was at the beginning of regular opioid use the
more likely they were to drop out of OMT. We did not
examine OMT participants’ dropout rate; nonetheless,
research shows a close link between younger age and
dropout.18,57,58
Strengths and Limitations
When interpreting these results, some limitations must be
taken into account. The current study was based on
a relatively small sample, which reduces the power to
detect weaker findings. We were still able to detect indi-
vidual change and correlates of change. Besides, this study
consists of self-selected participants in a limited geogra-
phical area. Thus, we cannot claim our results to be repre-
sentative for the Norwegian OMT population.
Nevertheless, there were significant similarities between
participants’ sociodemographic characteristics and the
Norwegian OMT population.
The validity of self-reported drug use has been ques-
tioned: Magura, Kang59 found that self-reported substance
use often was underreported by individuals in a drug use
population. Several studies uses urine tests to validate
participants’ self-reported data.60–63 The lack of such
tests is a limitation in our study; it could have improved
the validity of our results. Even if research shows that
substance abusers’ self-reports vary depending on the
type of the used substance, research also shows that self-
reports are consistent with urine tests, and therefore can be
a reliable data source.63–65 Additionally, self-selected par-
ticipants may be more committed to the study, and the
short-recall periods in our study can lead to a more accu-
rate reporting.
Other studies have detected effects of domain-specific
QOL indicators such as social QOL66,67 and environmental
QOL,67–69 while our study did not find such relationships.
Several methodological factors might have contributed to
our study not detecting any domain-specific associations:
the sample size was not big enough to detect any impact,
other domains besides those we examined may have
affected the overall QOL, or the QOL-questions in
KVARUS were to general and did not make explicit casual
relations among issues and substance use.42
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OMT participants’ natural treatment progression is
rarely examined,66 but the current study examines partici-
pants’ adverse experiences, resources, polydrug use, and
their potential change in treatment progression. This is one
of the uniqueness of this study. In addition, the frequency
of the follow-up, every third month, is a strength due to
reduced recall bias. Participants are to a greater extent
enabled to recall events that happened within a three
months’ time, in contrast to events that had a longer recall
period.70
Conclusion
The main objective was to examine the association between
OMT and subsequent polydrug use/opioid use, and whether
social factors and QOL were associated with such use during
the first 12 months in OMT. Our results show that OMT is
significantly related to patients’ opioid use, but seems to be
less important when it comes to polydrug use. This is also in
line with previous research. Our findings add QOL as an
important factor in relation to opioid use during OMT.
Clinicians should therefore give a particular attention to their
participants’ overall QOL in OMT, because a simple measure
of overall QOL can predict whether they are at risk of using
opioids. Clinicians can also gain insight to other aspects that
can affect the patients’ opioid use. This knowledge can be
used actively in treatment to improve patient QOL and thereby
may help reducing, and potentially prevent, patients from
using opioids.With such knowledge, we have a greater oppor-
tunity to intervene and reduce dropout from OMT. Besides,
the lack of significant results in relation to social dimensions
may imply that, apart from age, participants’ life story is of
minor importance in reducing polydrug use. Rather, it is the
participants’ current situation that is important.
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